API China 2026 was officially inaugurated today alongside co located industry exhibitions including PharmChina 2026, NHNE 2026, PHARMPACK 2026, and SINOPHEX 2026, bringing together the full spectrum of pharmaceutical manufacturing, healthcare, nutraceutical, packaging, equipment, and supply chain ecosystems under one integrated industry platform in China.
The inauguration ceremony witnessed participation from pharmaceutical industry leaders, manufacturing companies, technology providers, healthcare enterprises, industry associations, and international delegates, reflecting China’s continuing importance in the global pharmaceutical and life sciences value chain.
Organised by Reed Sinopharm Exhibitions, API China has evolved over more than four decades into one of the country’s most influential pharmaceutical industry exhibitions, connecting global suppliers, buyers, manufacturers, innovators, and policy stakeholders.
This year’s combined exhibitions are expected to attract:
• More than 120,000 professional visitors and buyers
• Over 2,400 exhibitors across pharmaceutical and healthcare sectors
• More than 120,000 square metres of exhibition space
• Participation from 97 per cent of China’s Top 100 pharmaceutical companies
The exhibitions collectively showcase technologies, products, and services spanning:
• Active Pharmaceutical Ingredients
• Pharmaceutical Intermediates
• Biopharmaceutical Manufacturing
• CRO, CDMO, And CMO Services
• Pharmaceutical Packaging Solutions
• Smart Manufacturing Systems
• Pharmaceutical Processing Equipment
• Nutraceuticals And Health Ingredients
• Healthcare Distribution And Retail Solutions
• AI Driven Pharmaceutical Operations
• Sustainable Manufacturing Technologies
Industry experts expect this year’s exhibitions to focus strongly on biopharmaceutical scale up, advanced manufacturing automation, digital transformation across pharmaceutical operations, supply chain resilience, green manufacturing initiatives, and expanding cross border collaboration opportunities.
More than 50 concurrent conferences, technical forums, and industry discussions are scheduled during the event, addressing pharmaceutical policy trends, regulatory developments, biologics manufacturing, R&D innovation, packaging sustainability, and future healthcare market opportunities.
The co location of API China, PharmChina, NHNE, PHARMPACK, and SINOPHEX continues to strengthen the event’s positioning as one of Asia’s most comprehensive pharmaceutical and healthcare industry gatherings, offering participants direct access to manufacturing technologies, sourcing networks, strategic partnerships, and emerging market opportunities across the broader healthcare ecosystem.
